celecoxib has been researched along with Carcinoma, Non-Small Cell Lung in 82 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " The main toxicities were grades 1 and 2 nausea and esophagitis, and they were independent of the dose of celecoxib or radiotherapy schedule." | 5.11 | A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. ( Blumenschien, G; Brown, B; Chang, JY; Cox, JD; Fossella, F; Guerrero, T; Jeter, M; Kies, M; Komaki, R; Liao, Z; Milas, L; Smith, CM; Yuan, C, 2005) |
| "Celecoxib with CCRT was well tolerated; the incidence of symptomatic radiation pneumonitis was 6." | 2.90 | Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. ( Bi, N; Chen, D; Deng, L; Feng, Q; Fu, Z; Hu, C; Hui, Z; Liang, J; Liu, L; Lv, J; Wang, J; Wang, L; Wang, W; Wang, X; Xiao, Z; Yang, X; Zhang, T; Zhou, Z, 2019) |
| " The endpoints were overall survival (OS), progression-free survival (PFS), disease-free survival (DFS), objective response rate (ORR), disease control rate (DCR), pathological complete response (pCR), and adverse events (AEs)." | 2.82 | The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. ( Chen, XW; Gao, P; Huang, XZ; Li, JY; Li, TH; Li, Y; Song, YX; Sun, JX; Wu, ZH; Ye, SY; Zhao, JH, 2022) |
| "Celecoxib was given for a maximum of one year but was stopped earlier in case of disease progression or prohibitive toxicity." | 2.78 | Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. ( Bergman, B; Clinchy, B; Ek, L; Fohlin, H; Lamberg, K; Lindgren, A; Lindskog, M; Sederholm, C; Sörenson, S, 2013) |
| "Celecoxib was continued for 2 years or until progression." | 2.76 | Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213. ( Bae, K; Choy, H; Extermann, M; Gore, E; Langer, C; Movsas, B; Okunieff, P; Videtic, G, 2011) |
| "Cancer cachexia is a syndrome of progressive weight loss." | 2.76 | A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study. ( Bird, SP; Keogh, JW; MacLeod, RD; Rogers, ES; Stewart, J, 2011) |
| "Celecoxib was originally administered orally at 200 mg twice daily and the protocol subsequently increased the dose to 400 mg twice daily." | 2.75 | Biological activity of celecoxib in the bronchial epithelium of current and former smokers. ( Eapen, GA; Hong, WK; Jimenez, CA; Kim, ES; Kurie, JM; Lee, JJ; Liu, DD; Lotan, R; Mao, L; Morice, RC; Newman, RA; Tang, X; Wistuba, II, 2010) |
| "Celecoxib was continued until disease progression." | 2.74 | A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer. ( Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F, 2009) |
| "Celecoxib was administered at a starting dose of 400 mg orally twice daily without interruption, beginning on day 2 of cycle 1." | 2.72 | Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer. ( Argiris, A; Avram, MJ; Kut, V; Luong, L, 2006) |
| " Primary end points included evaluation of toxicity and determination of the OBD of celecoxib when combined with erlotinib." | 2.72 | A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. ( Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C, 2006) |
| "Lung cancer is the most typical form of cancer that results in death worldwide." | 1.91 | Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression. ( Asif, M; Kashan Theba, F; Khalid, Z; Mujtaba Ali, M; Qadir, A; Rizvi, F, 2023) |
| " This study aimed to investigate the anti-cancer potential of PPAR-γ agonist Pioglitazone combined with COX-2 inhibitor Celelcoxib in NSCLC." | 1.72 | Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer. ( Kiran, AVVVR; Krishnamurthy, PT; Kumari, GK, 2022) |
| "Lung cancer is one of the highest health risks caused by ionizing radiation, which induces both direct effects and non-targeted effects." | 1.48 | Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib. ( Hei, TK; Hu, W; Li, B; Li, P; Nie, J; Pei, H; Sun, F; Zhou, G, 2018) |
| "Evaluation of in-vivo anticancer activity of aerosolized Celecoxib encapsulated Nanolipidcarriers (Cxb-NLC) as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell lung cancer." | 1.39 | Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel. ( Chougule, MB; I, T; Patel, AR; Patlolla, R; Singh, M; Wang, G, 2013) |
| " The objective of this study was to evaluate the effect of various SPI, both alone and in combination with cisplatin, on three different non-small cell lung cancer (NSCLC) cell lines." | 1.35 | Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines. ( El-Hefnawy, T; Kilic, A; Landreneau, RJ; Luketich, JD; Schuchert, MJ, 2009) |
| "Treatment with celecoxib alone has no effect on the ERK1/2 activation, Rad51 mRNA and protein levels, however, combined treatment with gefitinib results in a significant reduction of phospho-ERK1/2 and Rad51 protein levels, and triggers the degradation of Rad51 via a 26S proteasome-dependent pathway." | 1.35 | The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. ( Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH, 2009) |
| "Perifosine is an orally bioavailable alkylphospholipid currently being tested in phase II clinical trials as a potential anticancer drug." | 1.35 | Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. ( Elrod, HA; Khuri, FR; Sun, SY; Yue, P, 2009) |
| " We carried out the in vitro study using selective COX-2 inhibitor celecoxib combined with EGFR-tyrosine kinase inhibitor (EGFR-TKI) ZD1839 on NSCLC cell lines to investigate the anti proliferation effect and the cell molecular mechanism." | 1.35 | Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. ( Chen, L; He, Y; Huang, H; Liao, H; Wei, W, 2008) |
| "Celecoxib by itself was found to have no effects on cell growth or apoptosis in any of the cell lines." | 1.34 | Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. ( Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A, 2007) |
| "Cotreatment with celecoxib abrogated the increase in levels of PGE(2) but not COX-2 induced by chemotherapy." | 1.33 | Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. ( Altorki, NK; Dannenberg, AJ; Duffield-Lillico, AJ; Golijanin, D; Port, JL; Subbaramaiah, K; Thaler, HT; Zhang, F, 2005) |
| "Chemotherapy for the treatment of brain metastases arising from non-small cell lung cancer (NSCLC) has been limited by poor efficacy and high toxicity." | 1.33 | [A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer]. ( Hada, M; Horiuchi, T, 2005) |
| "Lung cancer is one of the most common causes of cancer death worldwide." | 1.33 | Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells. ( Chen, CS; Kehrer, JP; Tong, Z; Wu, X, 2006) |
| "Treatment with celecoxib significantly reduced calcium ionophore-stimulated PGE2 production from AMs recovered from smokers." | 1.32 | Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers. ( Baratelli, F; Dubinett, SM; Holmes, EC; Mao, JT; Roth, MD; Serio, KJ; Strieter, RM; Zhu, L, 2003) |
| "Celecoxib was effective even when administered 12 h after CSC treatment." | 1.32 | Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2 ( Aggarwal, BB; Shishodia, S, 2004) |
| "Celecoxib treatment decreased cell survival, activated caspase cascades, and increased DNA fragmentation, all of which were abrogated when caspase 8 expression was silenced with caspase 8 siRNA." | 1.32 | Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. ( Khuri, FR; Liu, X; Sun, SY; Yue, P; Zhou, Z, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 46 (56.10) | 29.6817 |
| 2010's | 31 (37.80) | 24.3611 |
| 2020's | 5 (6.10) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, H | 1 |
| Huang, X | 1 |
| Xu, S | 2 |
| Shen, H | 1 |
| Zhang, P | 3 |
| Huang, Y | 1 |
| Jiang, J | 1 |
| Sun, Y | 1 |
| Jiang, B | 1 |
| Wu, X | 2 |
| Yao, H | 1 |
| Xu, J | 1 |
| Ye, SY | 1 |
| Li, JY | 1 |
| Li, TH | 1 |
| Song, YX | 1 |
| Sun, JX | 1 |
| Chen, XW | 1 |
| Zhao, JH | 1 |
| Li, Y | 2 |
| Wu, ZH | 1 |
| Gao, P | 1 |
| Huang, XZ | 1 |
| Qadir, A | 1 |
| Khalid, Z | 1 |
| Kashan Theba, F | 1 |
| Mujtaba Ali, M | 1 |
| Asif, M | 1 |
| Rizvi, F | 1 |
| Xiao, J | 1 |
| Wang, F | 1 |
| Lu, H | 1 |
| Zou, L | 1 |
| Tian, Q | 1 |
| Fu, Y | 1 |
| Lin, X | 1 |
| Liu, L | 2 |
| Yuan, P | 1 |
| Ni, X | 1 |
| Ma, T | 1 |
| Zeng, F | 1 |
| Xue, P | 1 |
| Xiu, R | 1 |
| Zhang, J | 2 |
| Ji, X | 1 |
| Hu, H | 1 |
| Lu, S | 1 |
| Dai, H | 1 |
| Chu, Q | 1 |
| Zhao, X | 1 |
| Duan, Q | 1 |
| Zhu, F | 1 |
| He, D | 1 |
| Song, E | 2 |
| Jiang, M | 2 |
| Song, Y | 2 |
| Bi, N | 1 |
| Liang, J | 1 |
| Zhou, Z | 2 |
| Chen, D | 1 |
| Fu, Z | 1 |
| Yang, X | 1 |
| Feng, Q | 1 |
| Hui, Z | 1 |
| Xiao, Z | 1 |
| Lv, J | 1 |
| Wang, X | 5 |
| Zhang, T | 1 |
| Deng, L | 1 |
| Wang, W | 1 |
| Wang, J | 1 |
| Hu, C | 1 |
| Wang, L | 1 |
| Lee, R | 1 |
| Choi, YJ | 1 |
| Jeong, MS | 1 |
| Park, YI | 1 |
| Motoyama, K | 1 |
| Kim, MW | 1 |
| Kwon, SH | 1 |
| Choi, JH | 1 |
| Kiran, AVVVR | 1 |
| Kumari, GK | 1 |
| Krishnamurthy, PT | 1 |
| Gulyas, M | 1 |
| Mattsson, JSM | 1 |
| Lindgren, A | 2 |
| Ek, L | 3 |
| Lamberg Lundström, K | 1 |
| Behndig, A | 1 |
| Holmberg, E | 2 |
| Micke, P | 1 |
| Bergman, B | 3 |
| Yi, L | 1 |
| Zhang, W | 1 |
| Zhang, H | 3 |
| Shen, J | 1 |
| Zou, J | 1 |
| Luo, P | 1 |
| Hu, W | 1 |
| Pei, H | 1 |
| Sun, F | 1 |
| Li, P | 1 |
| Nie, J | 1 |
| Li, B | 1 |
| Hei, TK | 1 |
| Zhou, G | 1 |
| Jin, YH | 1 |
| Li, WH | 1 |
| Bai, Y | 1 |
| Ni, L | 1 |
| Ramer, R | 1 |
| Walther, U | 1 |
| Borchert, P | 1 |
| Laufer, S | 1 |
| Linnebacher, M | 1 |
| Hinz, B | 1 |
| Krysan, K | 4 |
| Kusko, R | 1 |
| Grogan, T | 1 |
| O'Hearn, J | 1 |
| Reckamp, KL | 4 |
| Walser, TC | 1 |
| Garon, EB | 1 |
| Lenburg, ME | 1 |
| Sharma, S | 3 |
| Spira, AE | 1 |
| Elashoff, D | 2 |
| Dubinett, SM | 7 |
| Mu, XY | 1 |
| Dong, XL | 1 |
| Sun, J | 1 |
| Ni, YH | 1 |
| Dong, Z | 1 |
| Li, XL | 1 |
| Sun, EL | 1 |
| Yi, Z | 1 |
| Li, G | 1 |
| Li, Z | 2 |
| Wang, K | 2 |
| An, MW | 1 |
| Mandrekar, SJ | 1 |
| Edelman, MJ | 3 |
| Sargent, DJ | 1 |
| Chen, J | 1 |
| Shen, P | 1 |
| Zhang, XC | 1 |
| Zhao, MD | 1 |
| Zhang, XG | 1 |
| Yang, L | 1 |
| Ren, P | 1 |
| Koczywas, M | 1 |
| Cristea, MC | 1 |
| Dowell, JE | 1 |
| Wang, HJ | 1 |
| Gardner, BK | 2 |
| Milne, GL | 2 |
| Figlin, RA | 3 |
| Fishbein, MC | 1 |
| Elashoff, RM | 2 |
| Hou, LC | 1 |
| Huang, F | 1 |
| Xu, HB | 1 |
| Li, N | 1 |
| Li, H | 1 |
| Su, F | 1 |
| Li, J | 1 |
| Ma, X | 1 |
| Gong, P | 1 |
| Zang, Y | 1 |
| Lee, JJ | 2 |
| Gadgeel, SM | 4 |
| Wozniak, A | 3 |
| Ruckdeschel, JC | 2 |
| Heilbrun, LK | 2 |
| Venkatramanamoorthy, R | 2 |
| Chaplen, RA | 1 |
| Kraut, MJ | 2 |
| Kalemkerian, GP | 2 |
| Schneider, BJ | 1 |
| Wozniak, AJ | 1 |
| Worden, FP | 1 |
| Smith, DW | 1 |
| Chen, W | 1 |
| Kilic, A | 1 |
| Schuchert, MJ | 1 |
| Luketich, JD | 1 |
| Landreneau, RJ | 1 |
| El-Hefnawy, T | 1 |
| Ko, JC | 1 |
| Wang, LH | 1 |
| Jhan, JY | 1 |
| Ciou, SC | 1 |
| Hong, JH | 1 |
| Lin, ST | 1 |
| Lin, YW | 1 |
| Mutter, R | 1 |
| Lu, B | 1 |
| Carbone, DP | 2 |
| Csiki, I | 3 |
| Moretti, L | 1 |
| Johnson, DH | 5 |
| Morrow, JD | 3 |
| Sandler, AB | 2 |
| Shyr, Y | 2 |
| Ye, F | 1 |
| Choy, H | 3 |
| Elrod, HA | 1 |
| Yue, P | 5 |
| Khuri, FR | 4 |
| Sun, SY | 5 |
| Kim, ES | 1 |
| Hong, WK | 2 |
| Mao, L | 1 |
| Morice, RC | 1 |
| Liu, DD | 1 |
| Jimenez, CA | 1 |
| Eapen, GA | 1 |
| Lotan, R | 2 |
| Tang, X | 1 |
| Newman, RA | 2 |
| Wistuba, II | 1 |
| Kurie, JM | 1 |
| Klenke, FM | 1 |
| Abdollahi, A | 1 |
| Bischof, M | 1 |
| Gebhard, MM | 1 |
| Ewerbeck, V | 1 |
| Huber, PE | 1 |
| Sckell, A | 1 |
| Gore, E | 2 |
| Bae, K | 1 |
| Langer, C | 1 |
| Extermann, M | 1 |
| Movsas, B | 1 |
| Okunieff, P | 1 |
| Videtic, G | 1 |
| Koch, A | 1 |
| Sederholm, C | 2 |
| Kosieradzki, J | 1 |
| Lamberg, K | 2 |
| Thaning, L | 1 |
| Ydreborg, SO | 1 |
| Sörenson, S | 2 |
| Hodgson, L | 2 |
| Christenson, R | 1 |
| Jewell, S | 2 |
| Vokes, E | 1 |
| Kratzke, R | 1 |
| Groen, HJ | 1 |
| Sietsma, H | 1 |
| Vincent, A | 1 |
| Hochstenbag, MM | 1 |
| van Putten, JW | 1 |
| van den Berg, A | 1 |
| Dalesio, O | 1 |
| Biesma, B | 1 |
| Smit, HJ | 1 |
| Termeer, A | 1 |
| Hiltermann, TJ | 1 |
| van den Borne, BE | 1 |
| Schramel, FM | 1 |
| Rogers, ES | 1 |
| MacLeod, RD | 1 |
| Stewart, J | 1 |
| Bird, SP | 1 |
| Keogh, JW | 1 |
| Ma, J | 1 |
| George, SL | 1 |
| Lasalvia-Prisco, E | 1 |
| Goldschmidt, P | 1 |
| Galmarini, F | 1 |
| Cucchi, S | 1 |
| Vázquez, J | 1 |
| Aghazarian, M | 1 |
| Lasalvia-Galante, E | 1 |
| Golomar, W | 1 |
| Gordon, W | 1 |
| Fohlin, H | 1 |
| Lindskog, M | 1 |
| Clinchy, B | 1 |
| Wang, ZL | 1 |
| Fan, ZQ | 1 |
| Jiang, HD | 1 |
| Qu, JM | 1 |
| Patel, AR | 1 |
| Chougule, MB | 1 |
| I, T | 1 |
| Patlolla, R | 1 |
| Wang, G | 1 |
| Singh, M | 4 |
| Altorki, NK | 3 |
| Keresztes, RS | 2 |
| Port, JL | 2 |
| Libby, DM | 1 |
| Korst, RJ | 1 |
| Flieder, DB | 1 |
| Ferrara, CA | 1 |
| Yankelevitz, DF | 1 |
| Subbaramaiah, K | 2 |
| Pasmantier, MW | 1 |
| Dannenberg, AJ | 2 |
| Vokes, EE | 2 |
| Liao, Z | 3 |
| Milas, L | 3 |
| Komaki, R | 3 |
| Stevens, C | 1 |
| Cox, JD | 2 |
| Mao, JT | 2 |
| Roth, MD | 1 |
| Serio, KJ | 1 |
| Baratelli, F | 1 |
| Zhu, L | 1 |
| Holmes, EC | 1 |
| Strieter, RM | 1 |
| Shishodia, S | 2 |
| Aggarwal, BB | 2 |
| Koul, D | 1 |
| Põld, M | 1 |
| Põld, A | 1 |
| Dohadwala, M | 2 |
| Heuze-Vourc'h, N | 1 |
| Riedl, KL | 1 |
| Liu, X | 3 |
| Nugent, FW | 1 |
| Mertens, WC | 1 |
| Graziano, S | 1 |
| Levitan, N | 1 |
| Collea, R | 1 |
| Gajra, A | 2 |
| Marshall, J | 1 |
| McCann, J | 1 |
| Schroeder, CP | 1 |
| Lotan, D | 1 |
| Yuan, C | 1 |
| Kies, M | 1 |
| Chang, JY | 1 |
| Jeter, M | 1 |
| Guerrero, T | 1 |
| Blumenschien, G | 1 |
| Smith, CM | 1 |
| Fossella, F | 1 |
| Brown, B | 1 |
| Spano, JP | 1 |
| Chouahnia, K | 1 |
| Morère, JF | 1 |
| Zhang, F | 1 |
| Golijanin, D | 1 |
| Thaler, HT | 1 |
| Duffield-Lillico, AJ | 1 |
| Shaik, MS | 3 |
| Chatterjee, A | 3 |
| Jackson, T | 2 |
| Argiris, A | 2 |
| Kut, V | 1 |
| Luong, L | 1 |
| Avram, MJ | 1 |
| Altundag, O | 1 |
| Altundag, K | 1 |
| Boruban, C | 1 |
| Silay, YS | 1 |
| Sandler, A | 2 |
| Oates, J | 1 |
| Williams, MK | 1 |
| Dang, T | 1 |
| Kang, HK | 1 |
| Lee, E | 1 |
| Pyo, H | 1 |
| Lim, SJ | 1 |
| Hada, M | 1 |
| Horiuchi, T | 1 |
| Backhus, LM | 1 |
| Petasis, NA | 1 |
| Uddin, J | 1 |
| Schönthal, AH | 3 |
| Bart, RD | 1 |
| Lin, Y | 1 |
| Starnes, VA | 1 |
| Bremner, RM | 1 |
| Tong, Z | 1 |
| Chen, CS | 1 |
| Kehrer, JP | 1 |
| Fulzele, SV | 2 |
| Tucker, C | 1 |
| Lilenbaum, R | 1 |
| Socinski, MA | 1 |
| Hart, LL | 1 |
| Hariharan, S | 1 |
| Morrison, ME | 1 |
| Fayyad, R | 1 |
| Bonomi, P | 2 |
| Heath, EI | 1 |
| De Ruysscher, D | 1 |
| Bussink, J | 1 |
| Rodrigus, P | 1 |
| Kessels, A | 1 |
| Dirx, M | 1 |
| Houben, R | 1 |
| Wanders, R | 1 |
| Chen, S | 1 |
| Ali, S | 1 |
| Philip, PA | 1 |
| Ahmed, F | 1 |
| Sarkar, FH | 1 |
| Chen, L | 1 |
| He, Y | 1 |
| Huang, H | 1 |
| Liao, H | 1 |
| Wei, W | 1 |
| Backlund, MG | 1 |
| Amann, JM | 1 |
| Watson, D | 1 |
| Morrison, C | 1 |
| Kratzke, RA | 1 |
| Mauer, AM | 1 |
| Masters, GA | 1 |
| Bedor, M | 1 |
| Green, MJ | 1 |
| Mao, J | 1 |
| Inge, L | 1 |
| Rajasekaran, A | 1 |
| Agarwala, A | 1 |
| Fisher, W | 1 |
| Bruetman, D | 1 |
| McClean, J | 1 |
| Taber, D | 1 |
| Titzer, M | 1 |
| Juliar, B | 1 |
| Yu, M | 1 |
| Breen, T | 1 |
| Einhorn, LH | 1 |
| Hanna, N | 1 |
| Fidler, MJ | 1 |
| Patel, JD | 1 |
| Villaflor, VM | 1 |
| Coon, J | 1 |
| Buckingham, L | 1 |
| Kaiser, K | 1 |
| Basu, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase II Trial of Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer[NCT01503385] | Phase 2 | 100 participants (Anticipated) | Interventional | 2011-12-31 | Recruiting | ||
| Evaluation Of Celecoxib In Combination With Weekly Docetaxel In Elderly (70 Years) Or Poor Performance Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)[NCT00030407] | Phase 2 | 34 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| Evaluation Of Celecoxib In Combination With Docetaxel In The Treatment Of Advanced Non-Small Cell Lung Cancer Patients Previously Treated With Platinum Based Chemotherapy[NCT00030420] | Phase 2 | 24 participants (Actual) | Interventional | 2001-10-31 | Completed | ||
| A Phase I/II Trial of a COX-2 Inhibitor, Celebrex (Celecoxib), [National Screening Committee# 719627] With Limited Field Radiation for Intermediate Prognosis Patients With Locally Advanced Non-Small Cell Lung Cancer, With Analysis of Prognostic Factors[NCT00046839] | Phase 1/Phase 2 | 21 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Cox-2-Inhibitor and Chemotherapy in Non-Small Cell Lung Cancer. A Prospective Randomized Double-Blind Study[NCT00300729] | Phase 3 | 319 participants (Actual) | Interventional | 2006-05-31 | Active, not recruiting | ||
| 0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients[NCT00771953] | Phase 2 | 109 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Radiosensitization With a COX-2 Inhibitor (Celecoxib), With Chemoradiation for Cancer of the Head and Neck[NCT00581971] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Phase I/II Trial Of Weekly Irinotecan And Docetaxel With The Addition Of Celecoxib In Advanced Non-Small Cell Lung Cancer[NCT00073866] | Phase 1/Phase 2 | 0 participants | Interventional | 2003-06-30 | Completed | ||
| A Phase I Trial Of A COX-2 Inhibitor (Celecoxib) In Combination With An EGFR Inhibitor (OSI-774) In Metastatic Non-Small Cell Lung Cancer[NCT00072072] | Phase 1 | 0 participants | Interventional | 2003-08-31 | Completed | ||
| Randomized Phase II Study of Eicosanoid Pathway Modulators and Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer[NCT00070486] | Phase 2 | 140 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Patients were followed for at least 90 days from start of RT and carefully evaluated with respect to treatment morbidity. A dose limiting toxicity (DLT) was defined as grade 3 or 4 nonhematologic (excluding nausea, vomiting, and alopecia) and grade 4 hematologic toxicities. Six patients were to be accrued at each dose level. If no more than three of the six patients experienced a DLT then that dose level was considered acceptable and dose escalation occurred by accruing six more patients at the next dose level. Otherwise, the preceding dose level, if any, would be declared the MTD. The MTD would be used for the Phase II arm. At a given dose, the probability of halting dose escalation when the true toxicity is 50% or higher is at least 66% (power). In addition, if the true DLT rate is instead 20%, there will still be a 10% probability of halting dose escalation at a given dose level (type I error).~Rating scale: 0 = not the MTD, 1 = MTD" (NCT00046839)
Timeframe: Start of treatment to 90 days
| Intervention | units on a scale (Number) |
|---|---|
| Phase I: Celecoxib 200mg BID + RT | 0 |
| Phase I: Celecoxib 400mg BID + RT | 1 |
Because only 21 patients (18 analyzable) out of 128 planned were accrued on this study, all analyzable patients were combined to report overall survival. The original study design planned for a comparison to a historical control, but due to the small number of patients, survival time is only reported, not tested. (NCT00046839)
Timeframe: From randomization to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 12 months.
| Intervention | years (Median) |
|---|---|
| Experimental: Phase I/II: Celecoxib 200 or 400mg BID + RT | 10.0 |
For determining progression-free survival, progression was determined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0). Progression was defined as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. (NCT00771953)
Timeframe: From the date of randomization until the first date that recurrent or progressive disease is objectively documented.
| Intervention | days (Median) |
|---|---|
| Apricoxib Plus Docetaxel | 75 |
| Placebo Plus Docetaxel | 97 |
| Apricoxib Plus Pemetrexed | 103 |
| Placebo Plus Pemetrexed | 98 |
Evaluate the response to concurrent celecoxib, carboplatin, paclitaxel, and radiotherapy in the treatment of locally advanced SSC of the head and neck. Response is determined by local control only, local and distant metastasis, distant metastasis only, second primary, and surgical salvage. (NCT00581971)
Timeframe: 2 years from end of treatment (Radiation therapy)
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Local Control Only | Local Control and Distant Metastasis | Distant Metastatsis Only | Secondary Primary - Site Unknown | Surgical Salvage | |
| Recurrence | 6 | 2 | 1 | 2 | 3 |
Particpants experiencing Acute Toxicities > Grade 3 (NCT00581971)
Timeframe: 2 years from radiation therapy
| Intervention | participants (Number) | ||
|---|---|---|---|
| Hematologic | Dermatitis | Mucositis/Dysphagia | |
| Acute Toxicity | 12 | 7 | 16 |
10 reviews available for celecoxib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
The Efficacy and Safety of Celecoxib in Addition to Standard Cancer Therapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; ErbB Receptors; Humans; Lung Neoplasms; | 2022 |
Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Lung Neoplasms; Publ | 2018 |
Efficacy and safety profile of celecoxib for treating advanced cancers: a meta-analysis of 11 randomized clinical trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cardiovascul | 2014 |
Does celecoxib improve the efficacy of chemotherapy for advanced non-small cell lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Lung Ne | 2016 |
Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting.
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Ce | 2003 |
Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cele | 2003 |
Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Humans | 2004 |
COX-2 inhibition and lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung | 2004 |
Celecoxib and radiation therapy in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topi | 2004 |
[Cyclooxygenase 2 inhibitors and lung carcinoma].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cele | 2004 |
28 trials available for celecoxib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemoradi | 2019 |
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Celecoxib; Humans; Lung Neoplasms; Pyrazoles; Random All | 2014 |
Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2015 |
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2008 |
Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecox | 2008 |
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2009 |
Biological activity of celecoxib in the bronchial epithelium of current and former smokers.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Proliferation; D | 2010 |
Phase I/II trial of a COX-2 inhibitor with limited field radiation for intermediate prognosis patients who have locally advanced non-small-cell lung cancer: radiation therapy oncology group 0213.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclo | 2011 |
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cycloox | 2011 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arac | 2011 |
Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2011 |
A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), resistance training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients--ACCeRT study.
Topics: Adult; Amino Acids, Essential; Cachexia; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modalit | 2011 |
Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies.
Topics: Acetylcysteine; Angiogenesis Inhibitors; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Carci | 2012 |
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell | 2013 |
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell | 2003 |
Docetaxel and cyclooxygenase-2 inhibition with celecoxib for advanced non-small cell lung cancer progressing after platinum-based chemotherapy: a multicenter phase II trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 2005 |
A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Combined | 2005 |
Phase I and pharmacokinetic study of docetaxel, irinotecan, and celecoxib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camp | 2006 |
Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antineoplastic Agents, Phytogenic; Ant | 2005 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2006 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin | 2006 |
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 2007 |
Concurrent celecoxib versus placebo in patients with stage II-III non-small cell lung cancer: a randomised phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; C | 2007 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-C | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2008 |
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell L | 2008 |
44 other studies available for celecoxib and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Discovery of novel hybrids of diaryl-1,2,4-triazoles and caffeic acid as dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase for cancer therapy.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Caffeic Acids; Carcinoma, Non-Small-C | 2016 |
Celecoxib and bevacizumab synergistically inhibit non-small cell lung cancer by inducing apoptosis and modulating VEGF and MMP-9 expression.
Topics: Apoptosis; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferat | 2023 |
Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Proliferation; Cyclooxygenase 2 | 2019 |
Celecoxib enhances the sensitivity of non-small-cell lung cancer cells to radiation-induced apoptosis through downregulation of the Akt/mTOR signaling pathway and COX-2 expression.
Topics: A549 Cells; Animals; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation | 2019 |
Hyaluronic Acid-Decorated Glycol Chitosan Nanoparticles for pH-Sensitive Controlled Release of Doxorubicin and Celecoxib in Nonsmall Cell Lung Cancer.
Topics: A549 Cells; Animals; Biological Transport; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chitosan; Dela | 2020 |
Celecoxib and Afatinib synergistic enhance radiotherapy sensitivity on human non-small cell lung cancer A549 cells.
Topics: A549 Cells; Afatinib; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Survival; Cyclooxyg | 2021 |
Preliminary evaluation of anticancer efficacy of pioglitazone combined with celecoxib for the treatment of non-small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Non-Small-Cell Lung | 2022 |
Epithelial-mesenchymal transition in non-targeted lung tissues of Kunming mice exposed to X-rays is suppressed by celecoxib.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Ce | 2018 |
Efficacy of erlotinib and celecoxib for patients with advanced non-small cell lung cancer: A retrospective study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc | 2019 |
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tu | 2013 |
PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Growth Processes; Cell Line, Tumor; Cyclo | 2014 |
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lun | 2014 |
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, No | 2014 |
Combined treatment of XIAP-targeting shRNA and celecoxib synergistically inhibits the tumor growth of non‑small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell L | 2015 |
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell | 2015 |
A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials, Ph | 2017 |
Efficacy of signal pathway inhibitors alone and in combination with Cisplatin varies between human non-small cell lung cancer lines.
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Chromones; Cisplatin; Cyclooxygenase In | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small | 2009 |
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; | 2009 |
Celecoxib enhances radiation response of secondary bone tumors of a human non-small cell lung cancer via antiangiogenesis in vivo.
Topics: Angiogenesis Inhibitors; Animals; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Di | 2011 |
ROC curve estimation under test-result-dependent sampling.
Topics: Biomarkers; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials, Phase III as Topic; Computer | 2013 |
Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line | 2013 |
Efficacy of aerosolized celecoxib encapsulated nanostructured lipid carrier in non-small cell lung cancer in combination with docetaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 2013 |
Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.
Topics: Aged; Bronchoalveolar Lavage; Bronchoscopy; Calcimycin; Carcinoma, Non-Small-Cell Lung; Case-Control | 2003 |
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates activation of cigarette smoke-induced nuclear factor (NF)-kappaB by suppressing activation of IkappaBalpha kinase in human non-small cell lung carcinoma: correlation with suppression of cyclin D1, COX-2
Topics: Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; | 2004 |
Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.
Topics: Carcinogens; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclin D1; Cyclooxygenase | 2004 |
Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Line, Tumor; Cell Survival | 2004 |
Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Northern; Blotting, Weste | 2004 |
Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Celecoxib; Ce | 2005 |
Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; B | 2005 |
Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibi | 2006 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lun | 2005 |
Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells.
Topics: Bronchi; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Re | 2005 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lu | 2005 |
Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Humans; Lung N | 2005 |
Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Celecoxib; Cyclooxygenase 2; Cycloox | 2006 |
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549.
Topics: Aerosols; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; C | 2006 |
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytoge | 2006 |
Did targeted therapy fail cyclooxygenase too?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxyg | 2006 |
Cellular FLICE-inhibitory protein down-regulation contributes to celecoxib-induced apoptosis in human lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regulati | 2006 |
CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2 | 2007 |
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non- | 2008 |
Novel strategies for the treatment of lung cancer: modulation of eicosanoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; C | 2008 |